ImageneBio (IMA) Competitors

$5.68 -0.23 (-3.89%)

As of 01:53 PM Eastern

IMA vs. VYGR, SGMT, HRTX, FENC, and RNAC

Should you buy ImageneBio stock or one of its competitors? MarketBeat compares ImageneBio with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with ImageneBio include Voyager Therapeutics (VYGR), Sagimet Biosciences (SGMT), Heron Therapeutics (HRTX), Adherex Technologies (FENC), and Cartesian Therapeutics (RNAC). These companies are all part of the "pharmaceutical products" industry.

How does ImageneBio compare to Voyager Therapeutics?

Voyager Therapeutics (NASDAQ:VYGR) and ImageneBio (NASDAQ:IMA) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their media sentiment, risk, institutional ownership, analyst recommendations, dividends, valuation, earnings and profitability.

48.0% of Voyager Therapeutics shares are held by institutional investors. Comparatively, 75.0% of ImageneBio shares are held by institutional investors. 12.7% of Voyager Therapeutics shares are held by company insiders. Comparatively, 5.9% of ImageneBio shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Voyager Therapeutics has a beta of 1.26, indicating that its stock price is 26% more volatile than the broader market. Comparatively, ImageneBio has a beta of 0.73, indicating that its stock price is 27% less volatile than the broader market.

In the previous week, ImageneBio had 3 more articles in the media than Voyager Therapeutics. MarketBeat recorded 7 mentions for ImageneBio and 4 mentions for Voyager Therapeutics. Voyager Therapeutics' average media sentiment score of 0.63 beat ImageneBio's score of 0.33 indicating that Voyager Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Voyager Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ImageneBio	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

ImageneBio has lower revenue, but higher earnings than Voyager Therapeutics. Voyager Therapeutics is trading at a lower price-to-earnings ratio than ImageneBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Voyager Therapeutics	$40.37M	5.89	-$119.72M	-$1.97	N/A
ImageneBio	$800K	75.35	-$45.35M	-$5.79	N/A

ImageneBio has a net margin of 0.00% compared to Voyager Therapeutics' net margin of -319.61%. ImageneBio's return on equity of -38.96% beat Voyager Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Voyager Therapeutics	-319.61%	-55.97%	-43.12%
ImageneBio	N/A	-38.96%	-34.60%

Voyager Therapeutics currently has a consensus price target of $16.50, suggesting a potential upside of 319.31%. ImageneBio has a consensus price target of $26.50, suggesting a potential upside of 368.20%. Given ImageneBio's higher possible upside, analysts plainly believe ImageneBio is more favorable than Voyager Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Voyager Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
ImageneBio	2 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.00

Summary

ImageneBio beats Voyager Therapeutics on 9 of the 16 factors compared between the two stocks.

How does ImageneBio compare to Sagimet Biosciences?

ImageneBio (NASDAQ:IMA) and Sagimet Biosciences (NASDAQ:SGMT) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, analyst recommendations, valuation, profitability, earnings, dividends and risk.

ImageneBio has a beta of 0.73, suggesting that its stock price is 27% less volatile than the broader market. Comparatively, Sagimet Biosciences has a beta of 3.6, suggesting that its stock price is 260% more volatile than the broader market.

ImageneBio has higher earnings, but lower revenue than Sagimet Biosciences. Sagimet Biosciences is trading at a lower price-to-earnings ratio than ImageneBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImageneBio	$800K	75.35	-$45.35M	-$5.79	N/A
Sagimet Biosciences	$2M	113.13	-$51.04M	-$1.34	N/A

Sagimet Biosciences' return on equity of -37.57% beat ImageneBio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ImageneBio	N/A	-38.96%	-34.60%
Sagimet Biosciences	N/A	-37.57%	-35.52%

75.0% of ImageneBio shares are owned by institutional investors. Comparatively, 87.9% of Sagimet Biosciences shares are owned by institutional investors. 5.9% of ImageneBio shares are owned by insiders. Comparatively, 14.7% of Sagimet Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Sagimet Biosciences had 4 more articles in the media than ImageneBio. MarketBeat recorded 11 mentions for Sagimet Biosciences and 7 mentions for ImageneBio. Sagimet Biosciences' average media sentiment score of 0.59 beat ImageneBio's score of 0.33 indicating that Sagimet Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ImageneBio	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Sagimet Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

ImageneBio presently has a consensus price target of $26.50, indicating a potential upside of 368.20%. Sagimet Biosciences has a consensus price target of $28.63, indicating a potential upside of 312.17%. Given ImageneBio's higher probable upside, research analysts clearly believe ImageneBio is more favorable than Sagimet Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImageneBio	2 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.00
Sagimet Biosciences	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.67

Summary

Sagimet Biosciences beats ImageneBio on 11 of the 16 factors compared between the two stocks.

How does ImageneBio compare to Heron Therapeutics?

ImageneBio (NASDAQ:IMA) and Heron Therapeutics (NASDAQ:HRTX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, profitability, risk, earnings, dividends and valuation.

ImageneBio has a beta of 0.73, suggesting that its share price is 27% less volatile than the broader market. Comparatively, Heron Therapeutics has a beta of 1.7, suggesting that its share price is 70% more volatile than the broader market.

Heron Therapeutics has higher revenue and earnings than ImageneBio. Heron Therapeutics is trading at a lower price-to-earnings ratio than ImageneBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImageneBio	$800K	75.35	-$45.35M	-$5.79	N/A
Heron Therapeutics	$154.90M	1.04	-$20.19M	-$0.18	N/A

ImageneBio has a net margin of 0.00% compared to Heron Therapeutics' net margin of -20.53%. ImageneBio's return on equity of -38.96% beat Heron Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ImageneBio	N/A	-38.96%	-34.60%
Heron Therapeutics	-20.53%	-7,747.30%	-8.94%

75.0% of ImageneBio shares are owned by institutional investors. Comparatively, 80.0% of Heron Therapeutics shares are owned by institutional investors. 5.9% of ImageneBio shares are owned by company insiders. Comparatively, 5.9% of Heron Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Heron Therapeutics had 4 more articles in the media than ImageneBio. MarketBeat recorded 11 mentions for Heron Therapeutics and 7 mentions for ImageneBio. ImageneBio's average media sentiment score of 0.33 beat Heron Therapeutics' score of 0.12 indicating that ImageneBio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ImageneBio	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Heron Therapeutics	1 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

ImageneBio presently has a consensus price target of $26.50, indicating a potential upside of 368.20%. Heron Therapeutics has a consensus price target of $4.50, indicating a potential upside of 426.32%. Given Heron Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Heron Therapeutics is more favorable than ImageneBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImageneBio	2 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.00
Heron Therapeutics	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20

Summary

Heron Therapeutics beats ImageneBio on 10 of the 17 factors compared between the two stocks.

How does ImageneBio compare to Adherex Technologies?

Adherex Technologies (NASDAQ:FENC) and ImageneBio (NASDAQ:IMA) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, analyst recommendations, risk, profitability, valuation, earnings and dividends.

Adherex Technologies has a beta of 0.91, meaning that its stock price is 9% less volatile than the broader market. Comparatively, ImageneBio has a beta of 0.73, meaning that its stock price is 27% less volatile than the broader market.

Adherex Technologies presently has a consensus price target of $14.80, indicating a potential upside of 55.54%. ImageneBio has a consensus price target of $26.50, indicating a potential upside of 368.20%. Given ImageneBio's higher probable upside, analysts plainly believe ImageneBio is more favorable than Adherex Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adherex Technologies	2 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.57
ImageneBio	2 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.00

Adherex Technologies has higher revenue and earnings than ImageneBio. Adherex Technologies is trading at a lower price-to-earnings ratio than ImageneBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adherex Technologies	$44.64M	7.36	-$9.74M	-$0.34	N/A
ImageneBio	$800K	75.35	-$45.35M	-$5.79	N/A

ImageneBio has a net margin of 0.00% compared to Adherex Technologies' net margin of -22.62%. ImageneBio's return on equity of -38.96% beat Adherex Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adherex Technologies	-22.62%	-183.18%	-15.31%
ImageneBio	N/A	-38.96%	-34.60%

55.5% of Adherex Technologies shares are owned by institutional investors. Comparatively, 75.0% of ImageneBio shares are owned by institutional investors. 10.7% of Adherex Technologies shares are owned by company insiders. Comparatively, 5.9% of ImageneBio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Adherex Technologies and Adherex Technologies both had 7 articles in the media. Adherex Technologies' average media sentiment score of 1.04 beat ImageneBio's score of 0.33 indicating that Adherex Technologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Adherex Technologies	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ImageneBio	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Adherex Technologies beats ImageneBio on 9 of the 15 factors compared between the two stocks.

How does ImageneBio compare to Cartesian Therapeutics?

Cartesian Therapeutics (NASDAQ:RNAC) and ImageneBio (NASDAQ:IMA) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, analyst recommendations, risk, profitability, valuation, earnings and dividends.

Cartesian Therapeutics has a beta of 0.58, meaning that its stock price is 42% less volatile than the broader market. Comparatively, ImageneBio has a beta of 0.73, meaning that its stock price is 27% less volatile than the broader market.

Cartesian Therapeutics presently has a consensus price target of $33.00, indicating a potential upside of 342.89%. ImageneBio has a consensus price target of $26.50, indicating a potential upside of 368.20%. Given ImageneBio's higher probable upside, analysts plainly believe ImageneBio is more favorable than Cartesian Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cartesian Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
ImageneBio	2 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.00

ImageneBio has lower revenue, but higher earnings than Cartesian Therapeutics. Cartesian Therapeutics is trading at a lower price-to-earnings ratio than ImageneBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cartesian Therapeutics	$2.80M	78.18	-$130.30M	-$5.90	N/A
ImageneBio	$800K	75.35	-$45.35M	-$5.79	N/A

ImageneBio has a net margin of 0.00% compared to Cartesian Therapeutics' net margin of -8,550.65%. Cartesian Therapeutics' return on equity of 0.00% beat ImageneBio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cartesian Therapeutics	-8,550.65%	N/A	-28.25%
ImageneBio	N/A	-38.96%	-34.60%

87.0% of Cartesian Therapeutics shares are owned by institutional investors. Comparatively, 75.0% of ImageneBio shares are owned by institutional investors. 37.2% of Cartesian Therapeutics shares are owned by company insiders. Comparatively, 5.9% of ImageneBio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Cartesian Therapeutics had 8 more articles in the media than ImageneBio. MarketBeat recorded 15 mentions for Cartesian Therapeutics and 7 mentions for ImageneBio. Cartesian Therapeutics' average media sentiment score of 0.42 beat ImageneBio's score of 0.33 indicating that Cartesian Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cartesian Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ImageneBio	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Cartesian Therapeutics beats ImageneBio on 10 of the 17 factors compared between the two stocks.

Get ImageneBio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IMA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IMA vs. The Competition

Export

Metric	ImageneBio	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$60.23M	$3.33B	$6.24B	$12.27B
Dividend Yield	N/A	2.31%	2.80%	5.35%
P/E Ratio	-0.98	18.29	20.39	25.30
Price / Sales	75.35	282.24	539.22	73.02
Price / Cash	N/A	125.29	43.26	56.33
Price / Book	0.49	6.72	9.83	6.90
Net Income	-$45.35M	$24.11M	$3.55B	$333.62M
7 Day Performance	6.99%	4.25%	0.73%	-0.15%
1 Month Performance	0.18%	-2.72%	-0.59%	1.68%
1 Year Performance	-57.12%	69.02%	36.42%	32.68%

ImageneBio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IMA ImageneBio	2.857 of 5 stars	$5.68 -3.9%	$26.50 +366.5%	-54.4%	$60.49M	$800K	N/A	70	News Coverage
VYGR Voyager Therapeutics	2.7711 of 5 stars	$4.22 +8.1%	$16.50 +291.5%	+32.9%	$254.07M	$40.37M	N/A	100
SGMT Sagimet Biosciences	3.2399 of 5 stars	$7.69 -0.5%	$28.63 +272.5%	+137.7%	$250.44M	$2M	N/A	8	Earnings Report Analyst Revision
HRTX Heron Therapeutics	2.224 of 5 stars	$1.33 +7.7%	$4.50 +239.6%	-47.0%	$249.95M	$154.90M	N/A	300	Earnings Report
FENC Adherex Technologies	4.0815 of 5 stars	$7.10 +5.6%	$14.80 +108.5%	+46.0%	$245.75M	$44.64M	N/A	10	News Coverage Positive News Earnings Report

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IMA) was last updated on 5/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ImageneBio (IMA) Competitors

IMA vs. VYGR, SGMT, HRTX, FENC, and RNAC

How does ImageneBio compare to Voyager Therapeutics?

Summary

How does ImageneBio compare to Sagimet Biosciences?

Summary

How does ImageneBio compare to Heron Therapeutics?

Summary

How does ImageneBio compare to Adherex Technologies?

Summary

How does ImageneBio compare to Cartesian Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMA vs. The Competition

ImageneBio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ImageneBio (IMA) Competitors

IMA vs. VYGR, SGMT, HRTX, FENC, and RNAC

How does ImageneBio compare to Voyager Therapeutics?

Do institutionals and insiders believe in VYGR or IMA?

Which has more risk and volatility, VYGR or IMA?

Does the media refer more to VYGR or IMA?

Which has preferable earnings and valuation, VYGR or IMA?

Is VYGR or IMA more profitable?

Do analysts recommend VYGR or IMA?

Summary

How does ImageneBio compare to Sagimet Biosciences?

Which has more risk & volatility, IMA or SGMT?

Which has preferable valuation and earnings, IMA or SGMT?

Is IMA or SGMT more profitable?

Do institutionals & insiders believe in IMA or SGMT?

Does the media prefer IMA or SGMT?

Do analysts prefer IMA or SGMT?

Summary

How does ImageneBio compare to Heron Therapeutics?

Which has more volatility and risk, IMA or HRTX?

Which has better valuation & earnings, IMA or HRTX?

Is IMA or HRTX more profitable?

Do insiders and institutionals believe in IMA or HRTX?

Does the media prefer IMA or HRTX?

Do analysts prefer IMA or HRTX?

Summary

How does ImageneBio compare to Adherex Technologies?

Which has more volatility & risk, FENC or IMA?

Do analysts prefer FENC or IMA?

Which has stronger valuation and earnings, FENC or IMA?

Is FENC or IMA more profitable?

Do insiders and institutionals believe in FENC or IMA?

Does the media favor FENC or IMA?

Summary

How does ImageneBio compare to Cartesian Therapeutics?

Which has more volatility & risk, RNAC or IMA?

Do analysts prefer RNAC or IMA?

Which has stronger valuation and earnings, RNAC or IMA?

Is RNAC or IMA more profitable?

Do insiders and institutionals believe in RNAC or IMA?

Does the media favor RNAC or IMA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMA vs. The Competition

ImageneBio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools